Kotak Securities has recommended a reduce rating on Cipla with a target price of Rs 684, in its February 13, 2015 research report.
"Cipla's revenues are a mixed bag, revenues are in line with expectations at Rs 26.2bn (up 2.8% YoY) but PAT was higher than expectations at Rs 3.27bn, primarily led by higher other operating income of Rs 1.4bn. Adjusted for higher other operating income, Cipla has reported below expected results. EBIDTA margins adjusted for other operating income dipped sharply to 15.7%, down 146bps YoY. We revise our FY15E EPS estimates by ~9.5% to factor lower EBIDTA margin guidance. We maintain our REDUCE rating on the stock with a TP of Rs 684, 20x FY17E EPS of Rs 30.8 plus NPV of Rs 67 (for inhalers).
"Cipla's (CIPL)'s launch of much awaited combination inhalers has led to sharp move in the stock price (from ~Rs450 levels to ~Rs 680). The launch does open up high margin/sustainable revenue stream for CIPL, but we believe most of it is priced in, hence we do not see any significant upside from current levels. We expect CIPL to register 15/21% CAGR in rev/PAT over FY14-17E led by robust 30%/20% CAGR in EU/US revenues coupled with high margin inhaler revenues. We maintain our REDUCE rating on the stock with a TP of Rs 684, 20x FY17E EPS of Rs 30.8 plus NPV of Rs 67 (for inhalers)", says Kotak Securities research report.
For all recommendations, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
To read the full report click here
Anda sedang membaca artikel tentang
Reduce Cipla, recommends Kotak Securities
Dengan url
https://untukkesehatanda.blogspot.com/2015/02/reduce-cipla-recommends-kotak-securities.html?m=0
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Reduce Cipla, recommends Kotak Securities
namun jangan lupa untuk meletakkan link
Reduce Cipla, recommends Kotak Securities
sebagai sumbernya
0 komentar:
Posting Komentar